PDL BioPharma Inc. manages a portfolio of patents and royalty assets related to the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. The company was founded in 1986 and is based in Incline Village, Nevada.
PDLI Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Pdl Biopharma Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Pdl Biopharma Inc ranked in the 6th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Pdl Biopharma Inc ended up being:
Interest coverage, a measure of earnings relative to interest payments, is -13.47; that's higher than only 8.91% of US stocks in the Healthcare sector that have positive free cash flow.
Its compound free cash flow growth rate, as measured over the past 5.73 years, is -0.26% -- higher than only 6.69% of stocks in our DCF forecasting set.
The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately only 10.15% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
IVC, PHG, CRY, LHCG, and TEVA can be thought of as valuation peers to PDLI, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
INCLINE VILLAGE, Nev., May 21, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that it has completed its previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem") (Nasdaq:…
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Ascendis Pharma A/S (NASDAQ: ASND ) (announced first-quarter results) Altimmune Inc (NASDAQ: ALT ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cue Biopharma Inc (NASDAQ: CUE ) (reacted to first-quarter results) Evoke Pharma Inc (NASDAQ: EVOK ) (announced FDA's conditional approval for the brand name Gimoti for its nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis) GENMAB A/S/S ADR (NASDAQ: GMAB ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Th...
INCLINE VILLAGE, Nev., May 18, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the final distribution ratio for the previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem")…
Please note that a slide presentation to accompany management's prepared remarks is available on the Investor Relations section of the PDL website at pdl.com. Joining me today from PDL are Dominique Monnet, President and CEO; and Ed Imbrogno, Vice President and Chief Financial Officer. Please turn to Slide 2, and let me remind you that during this call, management will be making forward-looking statements regarding the Company's financial performance and other matters and actual results may differ materially from those expressed in or implied by the forward-looking statements.